Request SampleTIL therapy - Pipeline Insight, 2021
SKU ID : DEL-19306971 | Publishing Date : 12-Oct-2021 | No. of pages : 60
Researcher’s, “TIL therapy – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in TIL therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
TIL therapy Understanding
TIL therapy: Overview
TIL (tumor-infiltrating lymphocyte) therapy is a type of cellular immunotherapy that may be used to treat head and neck squamous cell carcinoma, melanoma, lung cancer, genitourinary cancers and a growing list of other malignancies. Cellular immunotherapy leverages components of the patient’s own immune system to seek out and attack specific cancer cells. Because TILs come directly from the tumor, they already recognize many targets on the cancer cells. This makes them a very attractive therapy. Engineering TILs enhances their ability to fight the cancer cells. Currently, TIL therapies are only available through clinical trials. Currently, TIL therapy can be used to treat melanoma, variations of carcinoma, lung cancer, breast cancer, and genitourinary cancer.
"TIL therapy - Pipeline Insight, 2021" report by Researcher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TIL therapy pipeline landscape is provided which includes the disease overview and TIL therapy treatment guidelines. The assessment part of the report embraces, in depth TIL therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TIL therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence TIL therapy R&D. The therapies under development are focused on novel approaches to treat/improve TIL therapy.
TIL therapy Emerging Drugs Chapters
This segment of the TIL therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIL therapy Emerging Drugs
• LN-145: Iovance Therapeutics
Autologous tumour infiltrating lymphocytes is derived through isolation of a patient’s own naturally occurring TIL from a sample of cancerous tumor removed from the patient. The expanded and engineered TIL are then administered via intravenous infusion back to the patient as LN-145 (TIL therapy), with the intention that the TIL will target and infiltrate cancer in the patient and attack the cancer in greater number. It is currently being evaluated in Phase II clinical trial for the treatment of cervical cancer; colorectal cancer; Head and neck cancer; malignant melanoma; Non-small cell lung cancer.
• ITIL-168: Instil Bio
ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. ITIL-168 is manufactured with Instil’s proprietary, optimized, and scalable manufacturing process, which has been designed to capture and preserve the maximum diversity of each patient’s TILs; the manufacturing process also offers significant scheduling flexibility for patients and physicians at the time of both tumor resection and TIL treatment. The therapy is being investigated in Phase II stage of development for the treatment of malignant melanoma.
Further product details are provided in the report……..
TIL therapy: Therapeutic Assessment
This segment of the report provides insights about the different TIL therapy drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in TIL therapy
There are approx. 15+ key companies which are developing the therapies for TIL therapy. The companies which have their TIL therapy drug candidates in the most advanced stage, i.e. Phase II include, Iovance Therapeutics.
• Phases
Researcher’s report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
TIL therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
TIL therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TIL therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIL therapy drugs.
TIL therapy Report Insights
• TIL therapy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
TIL therapy Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing TIL therapy drugs?
• How many TIL therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIL therapy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIL therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TIL therapy and their status?
• What are the key designations that have been granted to the emerging drugs?
Geography Covered
• Global coverage
TIL therapy Understanding
TIL therapy: Overview
TIL (tumor-infiltrating lymphocyte) therapy is a type of cellular immunotherapy that may be used to treat head and neck squamous cell carcinoma, melanoma, lung cancer, genitourinary cancers and a growing list of other malignancies. Cellular immunotherapy leverages components of the patient’s own immune system to seek out and attack specific cancer cells. Because TILs come directly from the tumor, they already recognize many targets on the cancer cells. This makes them a very attractive therapy. Engineering TILs enhances their ability to fight the cancer cells. Currently, TIL therapies are only available through clinical trials. Currently, TIL therapy can be used to treat melanoma, variations of carcinoma, lung cancer, breast cancer, and genitourinary cancer.
"TIL therapy - Pipeline Insight, 2021" report by Researcher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TIL therapy pipeline landscape is provided which includes the disease overview and TIL therapy treatment guidelines. The assessment part of the report embraces, in depth TIL therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TIL therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence TIL therapy R&D. The therapies under development are focused on novel approaches to treat/improve TIL therapy.
TIL therapy Emerging Drugs Chapters
This segment of the TIL therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIL therapy Emerging Drugs
• LN-145: Iovance Therapeutics
Autologous tumour infiltrating lymphocytes is derived through isolation of a patient’s own naturally occurring TIL from a sample of cancerous tumor removed from the patient. The expanded and engineered TIL are then administered via intravenous infusion back to the patient as LN-145 (TIL therapy), with the intention that the TIL will target and infiltrate cancer in the patient and attack the cancer in greater number. It is currently being evaluated in Phase II clinical trial for the treatment of cervical cancer; colorectal cancer; Head and neck cancer; malignant melanoma; Non-small cell lung cancer.
• ITIL-168: Instil Bio
ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. ITIL-168 is manufactured with Instil’s proprietary, optimized, and scalable manufacturing process, which has been designed to capture and preserve the maximum diversity of each patient’s TILs; the manufacturing process also offers significant scheduling flexibility for patients and physicians at the time of both tumor resection and TIL treatment. The therapy is being investigated in Phase II stage of development for the treatment of malignant melanoma.
Further product details are provided in the report……..
TIL therapy: Therapeutic Assessment
This segment of the report provides insights about the different TIL therapy drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in TIL therapy
There are approx. 15+ key companies which are developing the therapies for TIL therapy. The companies which have their TIL therapy drug candidates in the most advanced stage, i.e. Phase II include, Iovance Therapeutics.
• Phases
Researcher’s report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
TIL therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
TIL therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TIL therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIL therapy drugs.
TIL therapy Report Insights
• TIL therapy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
TIL therapy Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing TIL therapy drugs?
• How many TIL therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIL therapy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIL therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TIL therapy and their status?
• What are the key designations that have been granted to the emerging drugs?
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
24/7 Research Support
Phone: +1 424 253 0807 
